[go: up one dir, main page]

BR0312960A - Composição de comprimido de liberação sustentada de pramipexol - Google Patents

Composição de comprimido de liberação sustentada de pramipexol

Info

Publication number
BR0312960A
BR0312960A BR0312960-8A BR0312960A BR0312960A BR 0312960 A BR0312960 A BR 0312960A BR 0312960 A BR0312960 A BR 0312960A BR 0312960 A BR0312960 A BR 0312960A
Authority
BR
Brazil
Prior art keywords
sustained release
release tablet
tablet composition
pramipexole sustained
tablet
Prior art date
Application number
BR0312960-8A
Other languages
English (en)
Inventor
Gregory E Amidon
Loksidh D Ganorkar
John M Heimlich
Ernest J Lee
Robert M Noack
Joseph P Reo
Connie J Skoug
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0312960A publication Critical patent/BR0312960A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"COMPOSIçãO DE COMPRIMIDO DE LIBERAçãO SUSTENTADA DE PRAMIPEXOL". A presente invenção refere-se a uma composição farmacêutica de liberação sustentada na forma de um comprimido de administração oral, compreendendo um sal hidrossolúvel de pramipexol, disperso em uma matriz compreendendo um polímero hidrófila e um amido com uma resistência à tensão de, pelo menos, 0,15 kN cm^ -2^ em uma fração sólida representativa do comprimido.
BR0312960-8A 2002-07-25 2003-07-25 Composição de comprimido de liberação sustentada de pramipexol BR0312960A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39844702P 2002-07-25 2002-07-25
US39842702P 2002-07-25 2002-07-25
US47951303P 2003-06-18 2003-06-18
PCT/US2003/023205 WO2004010997A1 (en) 2002-07-25 2003-07-25 Sustained-release tablet composition of pramipexole

Publications (1)

Publication Number Publication Date
BR0312960A true BR0312960A (pt) 2005-06-14

Family

ID=31192087

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312960-8A BR0312960A (pt) 2002-07-25 2003-07-25 Composição de comprimido de liberação sustentada de pramipexol

Country Status (41)

Country Link
US (2) US20050226926A1 (pt)
EP (2) EP1531814B1 (pt)
JP (1) JP4700963B2 (pt)
KR (1) KR100712832B1 (pt)
CN (1) CN1313092C (pt)
AP (1) AP2201A (pt)
AR (1) AR040681A1 (pt)
AT (1) ATE406162T1 (pt)
AU (1) AU2003261241B2 (pt)
BR (1) BR0312960A (pt)
CA (1) CA2492854C (pt)
CR (1) CR7661A (pt)
CU (1) CU23440B7 (pt)
CY (1) CY1110408T1 (pt)
DE (1) DE60323235D1 (pt)
DK (1) DK1531814T3 (pt)
EA (2) EA009663B1 (pt)
EC (1) ECSP055568A (pt)
ES (1) ES2310673T3 (pt)
GE (1) GEP20074048B (pt)
HK (1) HK10777456A1 (pt)
HR (1) HRP20041235B1 (pt)
IL (1) IL166078A0 (pt)
IS (1) IS7623A (pt)
MA (1) MA27328A1 (pt)
ME (1) MEP52308A (pt)
MX (1) MXPA05001054A (pt)
MY (1) MY138846A (pt)
NO (1) NO334298B1 (pt)
NZ (1) NZ537790A (pt)
OA (1) OA13303A (pt)
PA (1) PA8578301A1 (pt)
PE (1) PE20040130A1 (pt)
PL (1) PL215587B1 (pt)
PT (1) PT1531814E (pt)
RS (1) RS51719B (pt)
SI (1) SI1531814T1 (pt)
TW (1) TWI347849B (pt)
UY (1) UY27912A1 (pt)
WO (1) WO2004010997A1 (pt)
ZA (1) ZA200500439B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305252A1 (en) * 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CN1823091B (zh) 2003-07-11 2010-05-12 旭化成化学株式会社 功能性淀粉粉末
KR20070050081A (ko) * 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
RS52057B2 (sr) * 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
DE602004022205D1 (de) * 2004-09-09 2009-09-03 Psicofarma S A De C V Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie
EP1731514A1 (en) * 2005-06-02 2006-12-13 Sandoz AG Process for the preparation of Pramipexole
JP2009504748A (ja) * 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
US20080299189A1 (en) * 2007-06-04 2008-12-04 Drugtech Corporation Controlled release dopamine agonist compositions
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2010148409A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP2448411A4 (en) * 2009-07-02 2012-11-28 Supernus Pharmaceuticals Inc METHOD OF TREATING A NEUROLOGICAL DISORDER
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
EP2525786A2 (en) 2010-01-18 2012-11-28 Synthon BV Pramipexole extended release tablets
TR201001862A1 (tr) 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
JP2013526601A (ja) 2010-05-24 2013-06-24 ルピン・リミテッド プラミペキソールの徐放性製剤
KR101307334B1 (ko) * 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CN103520128B (zh) 2013-10-12 2018-08-21 石家庄杏林锐步医药科技股份有限公司 一种普拉克索的缓释片剂、制备方法及其用途
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
WO2018200387A1 (en) 2017-04-24 2018-11-01 Chase Therapeutics Corporation Compositions and method for treating depression
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN109316466B (zh) * 2017-07-31 2022-04-05 深圳翰宇药业股份有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CA3072994A1 (en) 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
CN113876729B (zh) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 一种盐酸普拉克索缓释片剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15735A (en) * 1856-09-16 Improvement in harvesters
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH649215A5 (de) 1981-04-29 1985-05-15 Hoffmann La Roche Pharmazeutische praeparate.
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4709712A (en) 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en) 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
HU210264B (en) 1989-06-09 1995-03-28 Upjohn Co Process for producing amines of condensed ring-systems containing nitrogen and pharmaceutical compositions containing them
GB9015822D0 (en) 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
NZ513456A (en) * 1997-07-01 2003-02-28 Pfizer Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) * 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
KR20010034588A (ko) * 1998-03-11 2001-04-25 피터 기딩스 조성물
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
DE19906290A1 (de) 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EP2090312A1 (en) 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating attention deficit disorder
AU5060499A (en) 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2394222A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6467637B2 (en) 2000-01-27 2002-10-22 The York Group, Inc. Death care merchandising system
NZ520975A (en) 2000-02-24 2004-03-26 Upjohn Co New drug combinations containing a norepinephrine reuptake inhibitor and an antimuscarinic agent for treating nervous system disorders
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
DE10138275A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
BR0215262A (pt) 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
JP2005538105A (ja) 2002-07-25 2005-12-15 ファルマシア・コーポレーション 水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003224467A1 (en) 2003-03-11 2004-09-30 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20050020589A1 (en) 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
KR20070050081A (ko) 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
EP1901720A2 (en) 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
EP1901721A1 (en) 2005-06-23 2008-03-26 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
JP2009504748A (ja) 2005-08-15 2009-02-05 ユニバーシティ オブ バージニア パテント ファウンデーション Ｒ（＋）プラミペキソールを用いた神経回復
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system

Also Published As

Publication number Publication date
EP1531814B1 (en) 2008-08-27
NO20050093L (no) 2005-02-24
CU23440B7 (es) 2009-10-16
EA200500079A1 (ru) 2005-06-30
ES2310673T3 (es) 2009-01-16
MA27328A1 (fr) 2005-05-02
OA13303A (en) 2007-04-13
SI1531814T1 (sl) 2008-12-31
CN1313092C (zh) 2007-05-02
JP4700963B2 (ja) 2011-06-15
AU2003261241B2 (en) 2009-06-18
PT1531814E (pt) 2008-10-29
US20050226926A1 (en) 2005-10-13
AR040681A1 (es) 2005-04-13
KR20050062516A (ko) 2005-06-23
US8399016B2 (en) 2013-03-19
DK1531814T3 (da) 2008-10-13
GEP20074048B (en) 2007-02-26
MEP52308A (en) 2011-02-10
MXPA05001054A (es) 2005-04-08
RS20050059A (sr) 2007-08-03
HRP20041235A2 (en) 2005-06-30
EA200702187A1 (ru) 2008-06-30
WO2004010997A1 (en) 2004-02-05
CA2492854A1 (en) 2004-02-05
ATE406162T1 (de) 2008-09-15
CN1671382A (zh) 2005-09-21
ZA200500439B (en) 2006-08-30
PL215587B1 (pl) 2013-12-31
PE20040130A1 (es) 2004-03-06
EA009663B1 (ru) 2008-02-28
TW200418523A (en) 2004-10-01
AP2201A (en) 2011-01-24
US20100316710A1 (en) 2010-12-16
UY27912A1 (es) 2004-02-27
ECSP055568A (es) 2005-04-18
NO334298B1 (no) 2014-01-27
HRP20041235B1 (hr) 2013-07-31
JP2005538106A (ja) 2005-12-15
CR7661A (es) 2005-06-08
MY138846A (en) 2009-07-31
IL166078A0 (en) 2006-01-15
NZ537790A (en) 2005-10-28
PA8578301A1 (es) 2004-07-20
WO2004010997A8 (en) 2005-02-24
EP1987832A1 (en) 2008-11-05
HK10777456A1 (en) 2007-11-30
PL375696A1 (en) 2005-12-12
RS51719B (sr) 2011-10-31
AU2003261241A1 (en) 2004-02-16
KR100712832B1 (ko) 2007-04-30
IS7623A (is) 2004-12-29
CA2492854C (en) 2009-10-20
DE60323235D1 (de) 2008-10-09
CY1110408T1 (el) 2015-04-29
EP1531814A1 (en) 2005-05-25
TWI347849B (en) 2011-09-01
AP2005003205A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
BR0312960A (pt) Composição de comprimido de liberação sustentada de pramipexol
BR0312870A (pt) Comprimido de liberação sustentada compreendendo reboxetina
BRPI0513846A (pt) formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
BRPI0411986A (pt) forma de dosagem farmacêutica multiparticulada, contendo substáncias peptìdicas ou protéicas ativas formuladas de maneira mucoadesiva, e um método para produzir a dita forma de dosagem farmacêutica
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
ES2421787T3 (es) Forma de dosificación de una vez al día de pramipexol
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BR9812001A (pt) Composição farmacêutica para combinação de descongestionante piperidinoalcanol
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
CO6150122A2 (es) Comprimidos pediatricos de capecitabina
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
BR0307048A (pt) Composição farmacêutica orodispersìvel de perindoprila
BG109430A (en) FLUKOONAZOLE CAPSULES WITH IMPROVED EXEMPTION
CO5680423A2 (es) Composicion de comprimido de liberacion sostenida de prami- presol
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
BR0306869A (pt) Composição farmacêutica orodispersìvel de piribedila
CO5680421A2 (es) Comprimido de liberacion sostenida que comprende reboxetina
BR0317412A (pt) Composição farmacêutica de liberação prolongada de fenitoìna de sódio e processo para sua preparação
ZA200705660B (en) Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate
DOP2003000570A (es) Forma de dosificacion de liberacion inmediata que contienen disperciones de farmaco solidos
BR0209023A (pt) Antagonista de lfa-1, antagonista de tnf-(alfa) e metotrexato, uso de um antagonista de lfa-1, um antagonista de tnf-(alfa) e metotrexato na preparação de um medicamento, composição e kit contendo os mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/428, 9/20, 9/28; A61P 25/16, 43/00

Ipc: A61K 31/428 (2011.01), A61K 9/20 (2011.01), A61K 9

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE)

Free format text: TRANSFERIDO DE: PHARMACIA CORPORATION

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.